Navin Pinto Selected Research

Navin Pinto Research Topics

19	Neuroblastoma 01/2023 - 06/2014
16	Neoplasms (Cancer) 01/2023 - 12/2009
2	Leukemia 01/2023 - 01/2018
2	Diffuse Intrinsic Pontine Glioma 01/2023 - 01/2023
2	Hypersensitivity (Allergy) 01/2018 - 12/2015
1	Osteosarcoma (Osteogenic Sarcoma) 01/2023
1	Brain Stem Neoplasms (Brain Stem Tumor) 01/2023
1	Fibrosarcoma 10/2022
1	Rhabdomyosarcoma 11/2021
1	Glioblastoma (Glioblastoma Multiforme) 01/2021
1	Medulloblastoma 01/2021
1	Desmoplastic Small Round Cell Tumor 12/2020
1	Neoplasm Metastasis (Metastasis) 06/2020
1	Hodgkin Disease (Hodgkin's Disease) 01/2020
1	Lymphoma (Lymphomas) 01/2020
1	Ischemia 01/2020
1	Melanoma (Melanoma, Malignant) 01/2020
1	Microsatellite Instability 01/2020
1	High-Frequency Hearing Loss 01/2019
1	Hepatitis 01/2018
1	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2018
1	Infections 01/2018
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2018
1	Fever (Fevers) 01/2018
1	Thymus Hyperplasia 01/2017
1	Chromosome Aberrations (Chromosome Abnormalities) 06/2016
1	Wernicke Encephalopathy (Wernicke's Encephalopathy) 12/2015
1	Neurologic Manifestations (Neurological Manifestations) 12/2015
1	Ataxia (Dyssynergia) 12/2015
1	Tachycardia (Tachyarrhythmias) 12/2015
1	Second Primary Neoplasms (Neoplasms, Second) 01/2015
1	Graft vs Host Disease (Graft-Versus-Host Disease) 12/2014
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2014

4	Chimeric Antigen ReceptorsIBA 01/2023 - 01/2018
3	3-Iodobenzylguanidine (Iobenguane)IBA 01/2023 - 12/2018
2	dinutuximabIBA 01/2023 - 01/2020
2	dipinacoline glutamateIBA 01/2023 - 01/2023
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2023 - 11/2021
2	Vorinostat FDA Link 11/2021 - 01/2018
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2021 - 12/2009
1	DNA (Deoxyribonucleic Acid)IBA 01/2023
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2023
1	RNA (Ribonucleic Acid)IBA 01/2023
1	lorlatinibIBA 01/2023
1	CrizotinibIBA 01/2023
1	Temozolomide (Temodar)FDA LinkGeneric 01/2023
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2022
1	ErbB Receptors (EGF Receptor)IBA 10/2022
1	4-hydroxycyclophosphamideIBA 11/2021
1	Vincristine (Oncovin)FDA LinkGeneric 11/2021
1	NucleotidesIBA 01/2021
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021
1	Phosphotransferases (Kinase)IBA 06/2020
1	pembrolizumabIBA 01/2020
1	Metformin (Glucophage)FDA LinkGeneric 01/2018
1	RetinoidsIBA 01/2018
1	Isotretinoin (Accutane)FDA LinkGeneric 01/2018
1	Sirolimus (Rapamycin)FDA Link 01/2018
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 11/2017
1	Proteins (Proteins, Gene)FDA Link 11/2017
1	LigandsIBA 11/2017
1	Formaldehyde (Formol)FDA Link 06/2016
1	ParaffinIBA 06/2016
1	Thiamine (Aneurin)FDA Link 12/2015
1	VitaminsIBA 12/2015
1	Tacrolimus (Prograf)FDA LinkGeneric 12/2014

16	Therapeutics 01/2023 - 05/2012
7	Drug Therapy (Chemotherapy) 01/2023 - 06/2014
4	Stem Cell Transplantation 01/2022 - 12/2014
2	Catheters 01/2023 - 01/2021
1	Investigational Therapies (Experimental Therapy) 01/2023
1	Combination Drug Therapy (Combination Chemotherapy) 01/2023
1	Hyperthermic Intraperitoneal Chemotherapy 12/2020
1	Neoadjuvant Therapy 12/2020
1	Hearing Aids (Hearing Aid) 01/2019
1	Induction Chemotherapy 01/2019
1	Blood Component Removal (Apheresis) 01/2018
1	Total Parenteral Nutrition 12/2015